Commenting on the approval, Ramesh Krishnamurthy, CEO of Vivimed Labs said, "We are very excited to receive approval to Vivimed's own product FEBRIL Syrup 100ml. Vivimed strategy is to increase its share of branded products in CIS Markets. Vivimed shall be launching this product in 2021. Our purpose is to offer innovative & top-quality formulations at affordable prices. This approval is testimony to Vivimed's growth strategy."
Vivimed Labs is a pharmaceutical and chemical products company. The company's segments include speciality chemicals and pharmaceuticals.
On a consolidated basis, the company posted a net loss of Rs 49.55 crore in Q3 FY21 as against a net loss of Rs 32.07 crore in Q3 FY20. Net sales jumped 40.6% year on year to Rs 277.94 crore in Q3 FY21.
